February 22, 2022 01:28 PM EST

Blatant abuse of Chapter 11? J&J says its use of 'Texas two-step' is all about fairness

Nicole DeFeudis

Editor

As a five-day trial over Johnson & Johnson’s controversial talc bankruptcy wrapped up last week, the pharma giant had a final argument to make: That …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Blatant abuse of Chapter 11? J&J says its use of 'Texas two-step' is all about fairness

Nicole DeFeudis

Editor

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Chinese drugmaker receives FDA warning letter after management hindered inspection

Bla­tant abuse of Chap­ter 11? J&J says its use of 'Texas two-step' is all about fair­ness

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Chi­nese drug­mak­er re­ceives FDA warn­ing let­ter af­ter man­age­ment hin­dered in­spec­tion

Blatant abuse of Chapter 11? J&J says its use of 'Texas two-step' is all about fairness

Applied Therapeutics' rare disease drug gets a CRL

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Chinese drugmaker receives FDA warning letter after management hindered inspection